Kressner U, Glimelius B, Bergström R, Påhlman L, Larsson A, Lindmark G
Department of Surgery, University Hospital, Uppsala, Sweden.
Br J Cancer. 1998 Jun;77(11):1848-51. doi: 10.1038/bjc.1998.307.
Serum p53 antibody levels were analysed using an enzyme-linked immunosorbent assay in serum samples obtained before surgery from 184 consecutive patients with primary colorectal cancer. Possible associations with tumour stage and tumour differentiation and the relation to patient survival time after a median follow-up of 6 years were studied. Analysis of serum p53 antibodies in the entire material demonstrated prognostic value in univariate analysis (P = 0.02); a finding that did not remain (P = 0.07) when the Dukes' stage was included in a multivariate analysis model. When the survival analysis was restricted to the potentially cured patients in Dukes' stages A-C, the serum p53 antibody levels retained independent prognostic value (P = 0.03). No clear association with tumour differentiation was found. We conclude that analysis of serum p53 antibodies may be of value for the identification of patients with different prognoses. This may be of relevance for selection of patients for adjuvant treatment.
采用酶联免疫吸附测定法，对184例连续的原发性结直肠癌患者术前采集的血清样本中的血清p53抗体水平进行了分析。研究了其与肿瘤分期、肿瘤分化的可能关联以及在中位随访6年后与患者生存时间的关系。对全部样本的血清p53抗体分析显示，单因素分析具有预后价值（P = 0.02）；当将Dukes分期纳入多因素分析模型时，这一结果不再显著（P = 0.07）。当生存分析仅限于Dukes A - C期可能治愈的患者时，血清p53抗体水平保留了独立的预后价值（P = 0.03）。未发现与肿瘤分化有明确关联。我们得出结论，血清p53抗体分析对于识别不同预后的患者可能具有价值。这可能与辅助治疗患者的选择有关。
